For many years, leading companies such as Boston Scientific and Stryker have engaged with Ansys, building a vision for personalized and digitalized healthcare to accelerate medical innovation. Executive leaders from these three organizations will share their vision and explain why adopting and deploying engineering simulation is a critical path forward for their organization. 

Pharmaceutical and biopharmaceutical companies of all sizes across the world are adopting in silico methods, and executives from Pfizer and Dr. Reddy's Laboratories and will explain the importance of deploying Computer Modeling & Simulation (CM&S) and paint their vision for the ongoing digitalization of pharmaceutical R&D and manufacturing activities. 

The importance of adopting in silico methods has become obvious, and pharmaceutical leaders are looking for the most efficient ways to adopt this technology quickly while minimizing risk and uncertainty. In silico veterans, including executives from Amgen, CEO of startup company Antleron, technical leaders from Ansys, and an academic thought leader will discuss the importance of an ecosystem and their recommendations for the successful adoption of CM&S during this prestigious panel discussion chaired by Ansys CTO, Prith Banerjee.